Special Issue

Machine Learning in Epidemiology

Message from the Guest Editors

Artificial intelligence (AI) and machine learning (ML) are revolutionizing epidemiology, offering unprecedented tools for analyzing vast amounts of health data and generating previously unobtainable insights. AI/ML approaches also encourage personalized healthcare by tailoring interventions based on individual risk factors and population-level trends, thus enhancing both prevention and treatment strategies. We invite submissions that explore the innovative use of AI and ML in epidemiological research, with a particularly interest in how these methodologies can be leveraged to improve disease outbreak predictions, support public health decision making, and utilize both structured and unstructured data to achieve more precise health outcomes. Additionally, we welcome research that highlights the challenges, ethical considerations, and future directions in AI/ML integration in the field of epidemiology. This Special Issue aims to contribute to the development of more effective, data-driven public health strategies essential for addressing current and emerging health challenges.

Guest Editors

Dr. Xingyu Zhang

School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA 15260, USA

Dr. Leming Zhou

Department of Health Information Management, University of Pittsburgh, Pittsburgh, PA 15260, USA

Deadline for manuscript submissions

closed (30 May 2025)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/216759

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI